Galectin Therapeutics (GALT) Assets Average (2011 - 2026)

Galectin Therapeutics' Assets Average history runs 16 years deep, the most recent figure standing at $17.6 million for Q1 2026.

• On a quarterly basis, Assets Average rose 30.6% year-over-year to $17.6 million in Q1 2026; TTM through Mar 2026 was $17.6 million, a 30.6% increase from a year earlier, with the FY2025 full-year figure at $18.5 million, down 18.97% from the prior year.
• Assets Average grew to $17.6 million in Q1 2026 per GALT's latest filing, from $16.2 million in the prior quarter.
• Across five years, Assets Average topped out at $37.7 million in Q1 2022 and bottomed at $12.6 million in Q2 2025.
• The 5-year median for Assets Average is $21.1 million (2023), against an average of $22.1 million.
• Across the five-year window, Assets Average surged 43.71% in 2022 and sank 53.07% in 2025, its largest moves.
• Year by year, Assets Average stood at $19.6 million in 2022, then rose by 28.48% to $25.2 million in 2023, then retreated by 7.74% to $23.2 million in 2024, then tumbled by 30.28% to $16.2 million in 2025, then rose by 8.93% to $17.6 million in 2026.
• Per Business Quant, the three latest GALT Assets Average figures stand at $17.6 million (Q1 2026), $16.2 million (Q4 2025), and $14.2 million (Q3 2025).